About HiberCell
HiberCell is a Healthcare company based in New York (United States) founded in 2015. HiberCell is focused on developing cancer treatment therapies. It operates on a HealthTech model. HiberCell has raised $128.15 million across 3 funding rounds from investors including Mount Sinai, Hercules Capital and Celgene. HiberCell has completed 1 acquisition, including Genuity Science. HiberCell offers products and services including HC-7366, HC-5404, and Odetiglucan. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Hibercell Inc. Its competitors include TScan Therapeutics, GigaGen and Shattuck Labs; 3 of its 3 listed competitors have raised funding.
Company details
HiberCell is engaged in pioneering cancer treatment paradigms by targeting adaptive stress mechanisms in tumors. The company is dedicated to addressing treatment resistance, relapse, and metastasis through innovative therapeutic candidates like HC-7366, HC-5404, and Odetiglucan. These solutions are designed to exploit stress-driven vulnerabilities in cancer cells, inhibit stress-mitigating pathways, and enhance immune responses in the tumor microenvironment. Operations are centered in the healthcare and biotechnology sector with a focus on improving patient outcomes through advanced clinical development.
- Headquarters New York, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hibercell.com
- Social LinkedIn
- Legal Name Hibercell Inc
- Total Equity Funding$128.15M (USD)
in 3 rounds
- Latest Funding Round$30M (USD), Debt – Conventional
May 2021
- InvestorsMount Sinai
& 10 more
- Investments & Acquisitions
Products & Services of HiberCell
HiberCell offers a comprehensive portfolio of products and services, including HC-7366, HC-5404, and Odetiglucan.
Designed to activate GCN2 kinase for stress response.
Developed to inhibit PERK for stress mitigation pathways.
Formulated to modulate immune response in tumor microenvironment.
Funding Insights of HiberCell
HiberCell has successfully raised a total of $128.15M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $30 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $128.15M
- Total Rounds 3
- Last Round Debt – Conventional — $30M
- First Round $60.75M
(Feb 2019)
- Investors Count 11
All 3 funding rounds of HiberCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $67.4M | Series B | – | Monashee Investment Management, Hercules Capital | |
| May 2021 | $30M | Debt – Conventional | – | – | |
| Feb 2019 | $60.75M | Series A | – | Arch Venture Partners |
11 investors in total: 11 institutional.
Investors in HiberCell
HiberCell has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Mount Sinai, Hercules Capital and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments. | 2018 | magneticvc.com | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Diversified investment management services are provided to clients. | 2011 | monasheecap.com | Boston, United States | |
Healthcare services and medical care are provided nationwide. | 1852 | mountsinai.org | United States | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Diversified investment management is offered to clients. | 2015 | trinitascmllc.com | Dallas, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for HiberCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HiberCell
30 people are tracked at HiberCell (11 in leadership, 11 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Beth Johnson | Executive Assistant & Head Of Administrative Operations | Leadership |
Michael Danielson | Executive Director Head Of CMC | Leadership |
Jeremy Drees | Director, Translational Medicine | Leadership |
Ari Nowacek | Co-Founder & Chief Business Officer | Leadership |
Crissy Dudgeon | Associate Director, InVitro Translational Oncology | Leadership |
Alexander Conte | Associate Director, Business Development | Leadership |
Nandita Bose | VP of Translational Immunology | Leadership |
José Iglesias | Consultant Chief Medical Officer | Leadership |
Eric Lightcap | Vice President | Leadership |
Haiguo Wu | Director of Bioinformatics | Leadership |
Kyle Michel | Associate Director, CMC Operations | Leadership |
Julio Aguirre-Ghiso | Co-Founder & Scientific Advisor | Board & advisors |
Christoph Klein | Scientific Advisor | Board & advisors |
Cindy Jacobs | Director | Board & advisors |
Jim Sullivan | Director | Board & advisors |
Colin Goddard | Director | Board & advisors |
Lisa M. Coussens | Scientific Advisor | Board & advisors |
Philip Rowlands | Scientific Advisor | Board & advisors |
Gregory L. Beatty | Scientific Advisor | Board & advisors |
Steven Gillis | Chairman & Acting CEO | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for HiberCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HiberCell
HiberCell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genuity Science.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based omics data analysis solutions are provided to researchers. | genuitysci.com | Boston, United States | 2013 | Aug 2021 | •••• |
Complete acquisition details for HiberCell
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of HiberCell
4 dated milestones of HiberCell across 6 years, from founding to its latest funding, stage changes and deals.
- Founded HiberCell is founded.
- Funding First funding round of $60.8M.
- Funding Latest funding round, Debt – Conventional, of $30.0M.
- Acquisition Acquires Genuity Science.
Competitors of HiberCell
HiberCell has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, GigaGen and Shattuck Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. |
Detailed competitors of HiberCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HiberCell
The website of HiberCell (hibercell.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 38.8% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as HiberCell (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hibercell
Complete news archive for HiberCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HiberCell
HiberCell was founded in 2015 and raised its 1st funding round 4 years after it was founded.
HiberCell is headquartered in New York, United States. It is registered at New York, New York, United States.
HiberCell is a funded company, having raised a total of $128.15M across 3 funding rounds to date. The company's 1st funding round was a Series A of $60.75M, raised on Feb 2019.
HiberCell is engaged in pioneering cancer treatment paradigms by targeting adaptive stress mechanisms in tumors. The company is dedicated to addressing treatment resistance, relapse, and metastasis through innovative therapeutic candidates like HC-7366, HC-5404, and Odetiglucan. These solutions are designed to exploit stress-driven vulnerabilities in cancer cells, inhibit stress-mitigating pathways, and enhance immune responses in the tumor microenvironment. Operations are centered in the healthcare and biotechnology sector with a focus on improving patient outcomes through advanced clinical development.
HiberCell's top competitors include GigaGen, Shattuck Labs and TScan Therapeutics.
HiberCell offers HC-7366, HC-5404, and Odetiglucan.
HiberCell has made 1 acquisition, including Genuity Science.
HiberCell has 11 investors. Key investors include Mount Sinai, Hercules Capital, Celgene, Arch Venture Partners, and Bristol-Myers Squibb.
HiberCell operates through Hibercell Inc.